RE:RE:RE:Doubt we ever hear from Charliefarley again .......Did you read Vaxart's Oral news release ??? Compare that to Goren's ...he promised news on Oral and then he buried it in USA Army news and warrants and law suits ........ect
“The latest data from the SARS-CoV-2 Hamster Challenge Study reinforces our belief that our oral COVID-19 vaccine candidate shows great promise.”
New pre-clinical histology data show that Vaxart’s oral vaccine protected against lung inflammation in hamster models
An article published in Nature Medicine reports data from a collaboration with Stanford University researchers on in vitro activity of Vaxart’s COVID-19 vaccine
Data from Vaxart’s Phase I COVID-19 trial expected to be released next week
SOUTH SAN FRANCISCO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today additional results from its SARS-CoV-2 Hamster Challenge Study, as well as a peer-reviewed publication in Nature Medicine resulting from a collaboration with prominent Stanford University scientists on COVID-19 vaccine candidates.
“The latest data from the SARS-CoV-2 Hamster Challenge Study reinforces our belief that our oral COVID-19 vaccine candidate shows great promise.” said Andrei Floroiu, chief executive officer of Vaxart. “Our oral vaccine could help fight the COVID-19 epidemic globally because it is stable at room-temperature making it easier to transport, store, and administer than injectables. It may also appeal to those uncomfortable with injections.”
New histology data from Vaxart’s SARS-CoV-2 Hamster Challenge Study showed that hamsters that received two doses of the oral tablet vaccine had a substantial reduction in lung inflammation as compared to unvaccinated hamsters.
Vaxart announced earlier results of its Hamster Challenge Study. These findings included:
- A 4- to 5-fold log reduction in lung viral load in hamsters that received two oral vaccine doses, as compared to non-vaccinated animals.
- Potent induction of antibody response, with serum IgG antibody titers above 10,000 in hamsters that received two oral vaccine doses.
- Oral vaccination protected as well as intranasal vaccination against intranasal challenge with respect to key indicators: protection from weight loss, protection from increase in lung weight, viral load reduction, and induction of serum IgG antibodies, demonstrating that mucosal protection by both routes of administration was comparable.
The company expects to submit the Hamster Challenge Study results to a peer-reviewed journal this quarter.
Red~One wrote: News , especially Covid news has to be accurate and without any promise or hints ..or else the SEC crack right down and put a CTO on the company....grow up Blig, show some backbone